bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 5.08M -57.5% |
| Revenue (ttm) | 5.90M -23.2% |
| Net Income | -15.19M |
| EPS | -59.70 |
| Shares Out | 1.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 278,093 |
| Open | 3.470 |
| Previous Close | 3.560 |
| Day's Range | 3.406 - 4.100 |
| 52-Week Range | 3.230 - 80.700 |
| Beta | -1.25 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cance... [Read more]
Financial Performance
In 2025, bioAffinity Technologies's revenue was $6.16 million, a decrease of -34.18% compared to the previous year's $9.36 million. Losses were -$14.91 million, 64.9% more than in 2024.
Financial StatementsNews
BioAffinity to present new perspectives on CyPath Lung at CHEST 2026
bioAffinity Technologies (BIAF) will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the evolving role of CyPath Lung in…
bioAffinity Technologies to Present New Perspectives on CyPath® Lung's Use for Cancer Risk Assessment at CHEST 2026
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies sponsors Learning Theater at CHEST 2026 on clinical use of CyPath Lung for detection of lung cancer.
BioAffinity Technologies to present new data at CHEST 2026
bioAffinity Technologies (BIAF) announced it will present new data at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the Company’s sputum-based tests in development to…
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies to present positive data on new test under development to measure lung inflammation in asthma and COPD at CHEST 2026.
bioAffinity Technologies Proxy statement: Proxy filing
bioAffinity Technologies filed a proxy statement on October 13, 2026, providing details for shareholder voting and corporate governance matters.
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J., Oct. 9, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASD...
BioAffinity Technologies announces closing of $4M registered direct financing
bioAffinity Technologies (BIAF) announced that it has closed its previously announced registered direct offering of shares of common stock with an institutional investor at a purchase price of $6.122,...
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--BIAF announces closing of $4 million registered direct financing of common stock and private placement priced at-the-market under Nasdaq rules.
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J., Oct. 8, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NAS...
bioAffinity Technologies Inc trading halted, volatility trading pause
12:07 EDT bioAffinity Technologies (BIAF) Inc trading halted, volatility trading pause
BioAffinity Technologies announces $4M registered direct offering
bioAffinity Technologies (BIAF) announced that it has entered into a definitive agreement with an institutional investor to sell shares of common stock at a purchase price of $6.122 in a…
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--BIAF Announces $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules.
BioAffinity announces Japan Patent Office issued notice of allowance for CyPath
bioAffinity Technologies (BIAF) announced that the Japan Patent Office has issued a Notice of Allowance indicating its intention to grant a patent to bioAffinity Technologies for the method of predict...
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies receives notice of allowance for new patent in Japan covering its noninvasive CyPath Lung diagnostic test for lung cancer.
BioAffinity reports over 100% growth in CyPath Lung sales through Q3
bioAffinity Technologies (BIAF) announced that sales of its CyPath Lung test for lung cancer increased more than 100% through the third quarter of 2026 compared to 2025. The number of…
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection an...
BioAffinity, AvMEDICAL deliver joint exhibition of CyPath Lung
bioAffinity Technologies (BIAF) is taking significant steps toward bringing its lung cancer test to the veterans who need it. This week, bioAffinity and its federal healthcare distribution partner AvM...
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity and AvMEDICAL jointly presented CyPath Lung for the first time under their new distribution agreement at NAVREF 2026 Annual Conference.
bioAffinity Technologies Proxy statement: Proxy filing
bioAffinity Technologies filed a proxy statement on September 29, 2026, providing details for shareholder voting and corporate governance matters.
BioAffinity to present clinical, veteran-focused data on CyPath Lung
bioAffinity Technologies (BIAF) announced it is presenting two posters highlighting its noninvasive lung cancer diagnostic, CyPath Lung, in clinical practice and ongoing research evaluating the techno...
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies will present two posters related to the CyPath Lung diagnostic test for lung cancer at the 2026 NAVREF Annual Conference.
bioAffinity Technologies Inc trading resumes
12:31 EDT bioAffinity Technologies (BIAF) Inc trading resumes
bioAffinity Technologies Inc trading halted, volatility trading pause
12:26 EDT bioAffinity Technologies (BIAF) Inc trading halted, volatility trading pause
BioAffinity Technologies announces grant of Hong Kong patent for CyPath Lung
bioAffinity Technologies (BIAF) announced that the Hong Kong Intellectual Property Department has granted a patent for the Company’s proprietary platform technology for predicting the likelihood of lu...
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity announces new Hong Kong patent that protects the proprietary technology behind its noninvasive CyPath Lung diagnostic for lung cancer.